Dapagliflozin to prevent atrial fibrillation recurrence after cardioversion
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have atrial fibrillation (AF) seen on an ECG and are scheduled for a cardioversion procedure within 7 to 26 days from today.
- You are 55 years or older.
- You are not currently taking a medication called an SGLT2 inhibitor (like dapagliflozin, empagliflozin, or canagliflozin).
- You have never been diagnosed with heart failure.
- You do not have type 1 diabetes.
- Your kidney function is good enough (eGFR above 25).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if dapagliflozin, a medication for diabetes and heart failure, can help prevent atrial fibrillation from returning after your first catheter ablation procedure for AF.
This study tests whether a medicine called dapagliflozin can reduce abnormal electrical activity in the heart by targeting fat around the heart in people with atrial fibrillation who are scheduled for a first catheter ablation. It may help improve the success of the procedure.
This trial tests if adding dapagliflozin (a diabetes drug) helps control heart rhythm in people recently diagnosed with atrial fibrillation. It's for those who haven't tried rhythm control treatments before.
This study tests whether a medication called an SGLT2 inhibitor (a type of diabetes drug) can improve the function of the upper left heart chamber in people who have paroxysmal atrial fibrillation, high blood pressure, and abnormal blood sugar levels. If you qualify, the trial may help your heart work better and reduce your risk of stroke.
This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
Hear when a new Atrial Fibrillation (AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.